Radiotherapy and zoledronic acid for metastatic bone tumor complicated with pain

Objective To investigate the effect of radiotherapy and zoledronic acid for metastatic bone tumor complicated with pain. Methods From January, 2015 to December, 2018, 62 patients with pain and metastatic bone tumor were randomly divided into an experimental group and a control group, 31 cases for each group. The experimental group were treated with radiotherapy and zoledronic acid, and the control group with radiotherapy. The effective rate, adverse reactions, quality of life assessment, and life span were observed in both groups. Results The effective rate of the experimental group was significantly higher than that of the control group (90.3% vs. 67.7%). The pain scores of the experimental group was significantly lower than those of the control group 7 and 28 days after the treatment (both P<0.05). The pain score was significantly lower 7, 14, and 28 days after than before the treatment in the experimental group; while the pain score was lower 14 and 28 days after than before the treatment in the control group (all P<0.05). The scores in the field of psychology were significantly higher after than before the treatment (P<0.05). The physical, psychological, social relationship, spiritual pillar/religion/personal belief, and quality of life assessment scores were higher after than before the treatment in the experimental group; the Physiology, psychological, social relationship and quality of life assessment score were higher after than before the treatment in the control group (all P<0.05). There were no statistical differences in adverse reaction and long-term survival between the two groups. Conclusions Radiotherapy combined with zoledronic acid can improve the efficacy of metastatic bone tumor and pain, without significantly increasing adverse reactions. Key words: Radiotherapy; Zoledronic acid; Malignant tumor; Metastatic bone tumor and pain